Neoadjuvant combination checkpoint blockade trial yields high response rates for patients with high-risk stage three melanoma
Combination checkpoint blockade before surgery (neoadjuvant therapy) produced a high response rate among patients with high-risk stage 3 melanoma, with nearly half having no sign...









